FOLH1 and prostate carcinoma: The main attraction for the use of PSMA for targeted therapy is its high level of expression that is increased by about 100- to 1000-folds higher in prostate cancer tissue compared with normal prostate tissue and the direct correlation between its level of expression and androgen independence, metastasis, and disease progression [16, 17].